Modest Efficacy for Methotrexate in Psoriasis

Save

Doubt remains regarding the appropriateness, efficacy and safety of methotrexate in the treatment of moderate to severe cutaneous psoriasis. Moreover, high dose, subcutaneous MTX has not been studied in a well-designed trial.

Curbside Consults - January 2017

Save

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.

The RheumNow Week in Review – 27 January 2017

Save

Dr. Cush reviews highlights from the past week on RheumNow.com.

The RheumNow Week in Review – 20 January 2017

Save

Dr. Jack Cush reviews highlights from the past week on RheumNow.

The RheumNow Week in Review – 13 January 2017

Save

Dr. Jack Cush reviews highlights from this past week on RheumNow.com:

The RheumNow Week in Review – 6 January 2017

Save

Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.

Happy New Year!

Guselkumab Efficacy and Tolerability in PsA/PsO

Save

New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.  

SPIRIT P1 Study - Ixekinumab Sustains Efficacy at 52 Weeks in Psoriatic Arthritis

Save

Ixekinumab (IXE) is an IGG4 monoclonal antibody bindings with high affinity to IL -17A.  Currently marketed at Taltz and approved for use in chronic plaque psoriasis, the agent is also being developed for use in psoriatic arthritis.

POSTURE Study: Apremilast Fails in Ankylosing Spondylitis

Save

ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.

Effective Interferon-Free Regimen for HCV-Cryoglobulinemic Vasculitis

Save

Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.

My Take on New Ocular Screening Guidelines for Plaquenil

Save

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).

Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis

Save

Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.  

Ilaris Gets FDA Approval for Rare Febrile Disorders

Save

Ilaris was previously approved for use in systemic JIA and CAPS. The FDA has expanded this to include TRAPS, Hyper-IgD and FMF based on clinical trials.

Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?

Save

Psoriasis and psoriatic arthritis are more prevalent, often more severe, and sometimes refractory to conventional treatments in HIV-positive patients, but clinicians are understandably concerned about moving on to immunosuppressive anti-tumor necrosis factor (TNF) agents when other treatments fai

RheumNow Week in Review - 29 July 2016

Save

Dr Jack Cush reviews this week's highlights from RheumNow.com.

Novel Rise of Combined Dermatology-Rheumatology Clinics

Save

Rheumatology News has a novel online report about combined rheumatology-dermatology clinics.  In the last several years, there have been a few of these in operation (Boston, Chicago, Rhode Island).

RheumNow Week in Review – 22 July 2016

Save

From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.

FDA Panel Recommends Brodalumab Approval in Psoriasis

Save

Valeant Pharmaceuticals International's experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.

Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee

Save

The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.